Haleon plc (NYSE:HLN) Shares Bought by Holistic Financial Partners

Holistic Financial Partners raised its holdings in Haleon plc (NYSE:HLN) by 14.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,207 shares of the company’s stock after purchasing an additional 1,518 shares during the period. Holistic Financial Partners’ holdings in Haleon were worth $116,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of HLN. Creative Planning grew its holdings in Haleon by 15.2% in the third quarter. Creative Planning now owns 285,227 shares of the company’s stock valued at $3,018,000 after purchasing an additional 37,566 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in Haleon by 44.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 25,560 shares of the company’s stock valued at $270,000 after purchasing an additional 7,856 shares during the period. International Assets Investment Management LLC acquired a new stake in Haleon in the third quarter valued at approximately $3,700,000. Ballentine Partners LLC boosted its stake in shares of Haleon by 53.1% in the third quarter. Ballentine Partners LLC now owns 22,831 shares of the company’s stock worth $242,000 after acquiring an additional 7,918 shares during the last quarter. Finally, Lake Street Advisors Group LLC boosted its stake in shares of Haleon by 5.4% in the third quarter. Lake Street Advisors Group LLC now owns 22,395 shares of the company’s stock worth $237,000 after acquiring an additional 1,143 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HLN. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Haleon currently has a consensus rating of “Moderate Buy” and an average price target of $10.95.

Haleon Stock Performance

Shares of Haleon stock opened at $10.08 on Monday. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The company has a market cap of $45.61 billion, a price-to-earnings ratio of 29.63, a PEG ratio of 2.82 and a beta of 0.28. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The business’s 50 day moving average price is $9.56 and its 200 day moving average price is $9.82.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.